AU2018339064A1 - Compositions and methods for modulating hair growth - Google Patents

Compositions and methods for modulating hair growth Download PDF

Info

Publication number
AU2018339064A1
AU2018339064A1 AU2018339064A AU2018339064A AU2018339064A1 AU 2018339064 A1 AU2018339064 A1 AU 2018339064A1 AU 2018339064 A AU2018339064 A AU 2018339064A AU 2018339064 A AU2018339064 A AU 2018339064A AU 2018339064 A1 AU2018339064 A1 AU 2018339064A1
Authority
AU
Australia
Prior art keywords
acid
electron transport
transport chain
inhibitor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018339064A
Other languages
English (en)
Inventor
Heather R. Christofk
Aimee FLORES
William E. Lowry
Matilde Miranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2018339064A1 publication Critical patent/AU2018339064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
AU2018339064A 2017-09-29 2018-09-28 Compositions and methods for modulating hair growth Abandoned AU2018339064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566031P 2017-09-29 2017-09-29
US62/566,031 2017-09-29
PCT/US2018/053351 WO2019067860A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (1)

Publication Number Publication Date
AU2018339064A1 true AU2018339064A1 (en) 2020-02-27

Family

ID=65903207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018339064A Abandoned AU2018339064A1 (en) 2017-09-29 2018-09-28 Compositions and methods for modulating hair growth

Country Status (16)

Country Link
US (1) US20200253917A1 (enExample)
EP (1) EP3687528A4 (enExample)
JP (1) JP2020536048A (enExample)
KR (1) KR20200062242A (enExample)
CN (1) CN111295188A (enExample)
AU (1) AU2018339064A1 (enExample)
BR (1) BR112020003349A2 (enExample)
CA (1) CA3077359A1 (enExample)
CL (1) CL2020000676A1 (enExample)
EA (1) EA202090855A1 (enExample)
IL (1) IL272827A (enExample)
MX (1) MX2020002389A (enExample)
PE (1) PE20210464A1 (enExample)
PH (1) PH12020500300A1 (enExample)
SG (2) SG10202109849SA (enExample)
WO (1) WO2019067860A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102440809B1 (ko) 2017-02-24 2022-09-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 Mpc 저해제를 사용하여 모발 성장을 촉진하는 조성물 및 방법
IL321754A (en) 2017-06-30 2025-08-01 Univ California Compositions and methods for modulating hair growth
US12649736B2 (en) 2019-12-20 2026-06-09 The Regents Of The University Of California Synthesis of compounds to promote hair growth
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
KR102561912B1 (ko) * 2021-04-09 2023-07-31 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물
CN113694063A (zh) * 2021-08-31 2021-11-26 佛山市第一人民医院（中山大学附属佛山医院） 一种组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
ES2312012T3 (es) * 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
EP1919449A2 (en) * 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8563500B2 (en) * 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
CN106880693A (zh) * 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法

Also Published As

Publication number Publication date
JP2020536048A (ja) 2020-12-10
CA3077359A1 (en) 2019-04-04
EP3687528A1 (en) 2020-08-05
CN111295188A (zh) 2020-06-16
EA202090855A1 (ru) 2020-06-26
BR112020003349A2 (pt) 2020-08-18
WO2019067860A1 (en) 2019-04-04
PE20210464A1 (es) 2021-03-08
IL272827A (en) 2020-04-30
PH12020500300A1 (en) 2020-11-09
MX2020002389A (es) 2020-10-01
EP3687528A4 (en) 2021-07-21
SG10202109849SA (en) 2021-10-28
CL2020000676A1 (es) 2020-09-25
SG11202001516QA (en) 2020-03-30
KR20200062242A (ko) 2020-06-03
US20200253917A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
US20200253917A1 (en) Compositions and methods for modulating hair growth
US20230190736A1 (en) Small molecule therapeutics for the treatment of viral infections
US20110311478A1 (en) Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
JP6796097B2 (ja) 食欲不振制御化合物の組成物および使用方法
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
CN111032035A (zh) 用于替司他赛和卡培他滨的给药方案
ES2902795T3 (es) Composición para uso crónico como compuesto para aumentar de peso
WO2024050145A1 (en) Thiostrepton dosing regimens
TW202122085A (zh) 治療血管畸形之方法
EP3366288B1 (en) Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity
HK40026046A (en) Compositions and methods for modulating hair growth
US20070293485A1 (en) Drug administration methods
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
WO2025166338A2 (en) Systemic mpc inhibition to reverse signs of aging
WO2020242910A1 (en) Compositions and methods for treating cancer
WO2009115429A1 (en) Food preparation and pharmaceutical composition containing an embryonic extract
US20160113955A1 (en) Compositions And Methods For Immunotherapy
HK40123938A (en) Thyroid beta-agonist dosing regimens for the treatment of x-ald
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
Hasan et al. Serum testosterone concentration in surgically castrated Black Bengal goats
RU2680393C1 (ru) Инъекционное средство для лечения гепатозов у крупного рогатого скота
WO2025117739A1 (en) Compositions and methods for treating cancer
WO2024035876A2 (en) Compositions and methods of treating cancer
RU2557889C1 (ru) Средство для лечения кокцидиозов у птиц и животных
HK40089161A (en) Nicotinamide adenine dinucleotide (nad) concentration increasing agent

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LOWRY, WILLIAM E.; CHRISTOFK, HEATHER R.; MIRANDA, MATILDE AND FLORES, AIMEE

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period